Hypermarcas (OTCMKTS:HYPMY – Get Free Report) shares crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $4.51 and traded as high as $4.51. Hypermarcas shares last traded at $4.41, with a volume of 33,566 shares.
Wall Street Analyst Weigh In
Separately, Zacks Research upgraded shares of Hypermarcas to a “hold” rating in a report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy”.
Get Our Latest Analysis on HYPMY
Hypermarcas Price Performance
Hypermarcas (OTCMKTS:HYPMY – Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The company reported $0.10 earnings per share for the quarter. The company had revenue of $383.13 million for the quarter. Hypermarcas had a net margin of 19.41% and a return on equity of 14.08%. As a group, sell-side analysts forecast that Hypermarcas will post 0.53 earnings per share for the current fiscal year.
About Hypermarcas
Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.
Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.
See Also
- Five stocks we like better than Hypermarcas
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Receive News & Ratings for Hypermarcas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypermarcas and related companies with MarketBeat.com's FREE daily email newsletter.
